3-Jun-2021    Phelan McDermid Syndrome Foundation - Interview with Neuren Pharmaceuticals about upcoming Phelan-McDermid clinical trial  
 
14-Jul-2020    Publication in Pediatric Neurology: Berry-Kravis E et al., A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Fragile X Syndrome  
 
14-Jul-2020    Poster at 72nd Annual Meeting of American Academy of Neurology  

Trofinetide: a novel approach to Rett syndrome. Neul JL, Percy AK, Benke TA, Berry-Kravis EM, Glaze DG, Jones NE, Youakim JM.

 		 
27-Mar-2019    Publication in Neurology®: Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome  
 
23-Jun-2016    Poster at Rettsyndrome.org 2016 Rett Syndrome Symposium  

Improving outcome measures for Rett Syndrome (RTT) clinical trials: Development of CSS/MBA change indexes to assess treatment outcome

 		 
22-Jun-2016    Presentation by Daniel Glaze, MD, at Rettsyndrome.org 2016 Rett Syndrome Symposium  

Past, Present and Future: A program to develop and establish Trofinetide as a safe and effective treatment for Rett syndrome

 		 
12-May-2016    Presentation at 6th Annual TBI Conference, Washington DC  

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients with Traumatic Brain Injury

 		 
22-Apr-2015    Poster at American Academy of Neurology 2015 Annual Meeting  

NNZ-2566: A Novel, Experimental Treatment for Rett Syndrome

 		 
15-May-2014    Poster at International Meeting for Autism Research (IMFAR)  

Improving outcome measures for Rett Syndrome (RTT) clinical trials: the development of RTT-specific anchors for the Clinical Global Impression Scale

 		 
30-Sep-2013    Poster at 2013 FRAXA Investigators Meeting  

The Impact of NNZ-2591 on the fmr1 Knockout Mouse Model of Fragile X Syndrome

 		 
4-Apr-2013    Poster at American Neuropsychiatric Association 2013 Annual Meeting  

The Impact of NNZ-2566 on the fmr1 Knockout Mouse Model of Fragile X Syndrome

 		 
1-Aug-2012    Presentation by Dr Mike Snape at ICare4Autism 2012 International Autism Conference  

NNZ-2566 - Rationale for use in Autism Spectrum Disorders